Non-Alkolik Yağlı Karaciğer Hastalığı Olan Çocuklarda Lipid Profilleri ve D Vitamini Düzeylerinin Yağlı Karaciğer Derecesi Üzerindeki Etkileri

Year 2025, Volume: 9 Issue: 2, 181 - 186, 31.08.2025

Arzu Gülseren , Didem Gulcu Taskin

https://doi.org/10.29058/mjwbs.1591828

Abstract

Amaç: Çalışmanın amacı hepatosteatoz hastalarının D vitamini, trigliserit ve kolesterol düzeylerini sağlıklı kontrol hastalarıyla karşılaştırmaktır.
Gereç ve Yöntemler: Çalışmamıza retrospektif olarak hepatosteatozlu 99 hasta ve sağlıklı kontrol hastaları dahil edildi. Çalışmaya dahil
edilen hastalar 2020-2023 yılları arasında çocuk gastroenteroloji polikliniğine başvuran hastalardı.
Bulgular: Çalışmamıza hepatosteatozlu 47 (%47,5) ve kontrol grubunda 52 (%52,5) olmak üzere toplam 99 hasta dahil edildi. Ortalama ALT
değerleri hepatosteatoz ve kontrol gruplarında sırasıyla 35,2 ± 19,5 ve 28,3 ± 13,0 idi (P= 0,039). Ortalama trigliserit (136 ± 28 vs 125 ± 24;
P= 0.042) ve kolesterol (165 ± 20 vs 154 ± 20; P= 0.010) düzeyleri hepatosteatoz grubunda kontrol grubuna göre daha yüksekti ve sonuç
anlamlı olarak farklı bulundu. Ortalama D vitamini düzeyleri gruplar arasında farklılık göstermedi. Her iki grupta da D vitamini eksikliği yüksek
bulundu, ancak gruplar arasında fark analiz edilmedi (%72.3 vs %61.5; P= 0.491).
Sonuç: Hepatosteatozlu hastalarda trigliserit ve kolesterol düzeyleri daha yüksek bulundu. Açlık kan şekeri hepatosteatoz grubunda
daha yüksektir. Bu sonuçlara ve literatüre dayanarak, hepatosteatozlu hastalar ilerleyen yıllarda metabolik sendrom ve ateroskleroz gibi
kardiyovasküler hastalıklar gibi önemli hastalıklar için risk oluşturmaktadır.

Keywords

Kolesterol , hepatosteatoz , trigliserid , D vitamini

Effects of Lipid Profiles and Vitamin D Levels on the Degree of Fatty Liver in Children with Non-Alcoholic Fatty Liver Disease

Abstract

Aim: The aim of the study was to compare vitamin D, triglyceride and cholesterol levels of hepatosteatosis patients with healthy control
patients.
Material and Methods: Ninety-nine patients with hepatosteatosis and healthy control patients were included in our study retrospectively.
The patients included in the study were patients who applied to the pediatric gastroenterology outpatient clinic between 2020 and 2023.
Results: A total of 99 patients, 47 (47.5%) with hepatosteatosis and 52 (52.5%) in the control group, were included in our study. Mean ALT
values were 35.2 ± 19.5 and 28.3 ± 13.0 in the hepatosteatosis and control groups, respectively (P= 0.039). Mean triglyceride (136 ± 28 vs
125 ± 24; P= 0.042) and cholesterol (165 ± 20 vs 154 ± 20; P= 0.010) levels were higher in the hepatosteatosis group than in the control
group and the result was found to be significantly different. Mean vitamin D levels did not differ between the groups. Vitamin D deficiency was
found to be high in both groups, but no difference was analyzed between the groups (72.3% vs 61.5%; P= 0.491).
Conclusion: Triglyceride and cholesterol levels were found to be higher in patients with hepatosteatosis. Fasting blood glucose is higher in
the hepatosteatosis group. Based on these results and the literature, patients with hepatosteatosis pose a risk for important diseases such
as metabolic syndrome and cardiovascular diseases such as atherosclerosis in the following years.

Keywords

Cholesterol , hepatosteatosis , triglyceride , vitamin D

References

• 1. Feldstein AE, Charatcharoenwitthaya P, Treeprasertsuk S, Benson JT, Enders FB, Angulo P. The natural history of non-alcoholic fatty liver disease in children: a follow-up study for up to 20 years. Gut. 2009 Nov;58(11):1538-44.
• 2. Vos MB, Abrams SH, Barlow SE, Caprio S, Daniels SR, Kohli R, Mouzaki M, Sathya P, Schwimmer JB, Sundaram SS, Xanthakos SA. NASPGHAN Clinical Practice Guideline for the Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease in Children: Recommendations from the Expert Committee on NAFLD (ECON) and the North American Society of Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN). J Pediatr Gastroenterol Nutr. 2017 Feb;64(2):319-334.
• 3. Sezer OB, Buluş D, Hızlı Ş, Andıran N, Yılmaz D, Ramadan SU. Low 25-hydroxyvitamin D level is not an independent risk factor for hepatosteatosis in obese children. J Pediatr Endocrinol Metab. 2016 Jul 1;29(7):783-8.
• 4. Cortez-Pinto H, Camilo ME. Non-alcoholic fatty liver disease/ non-alcoholic steatohepatitis (NAFLD/NASH): diagnosis and clinical course. Best Pract Res Clin Gastroenterol. 2004 Dec;18(6):1089-104.
• 5. Kitson MT, Roberts SK. D-livering the message: The importance of vitamin D status in chronic liver disease. J Hepatol 2012;57:897–909.
• 6. Bolland MJ, Grey AB, Ames RW, Mason BH, Horne AM, Gamble GD, Reid IR. The effects of seasonal variation of 25-hydroxyvitamin D and fat mass on a diagnosis of vitamin D sufficiency. Am J Clin Nutr. 2007 Oct;86(4):959-64.
• 7. Deurenberg P, Weststrate JA, Seidell JC. Body mass index as a measure of body fatness: age- and sex-specific prediction formulas. Br J Nutr. 1991 Mar;65(2):105-14.
• 8. Holick MF. Vitamin D deficiency. N Engl J Med 2007;357:266–81.
• 9. Candace Y. Parker-Autry, Kathryn L. Burgio, and Holly E. Richter. Vitamin D Status – A Clinical Review with Implications for the Pelvic Floor. Int Urogynecol J. 2012; 23(11): 1517–1526.
• 10. Lee SS, Park SH. Radiologic evaluation of nonalcoholic fatty liver disease. World J Gastroenterol 2014;20:7392.
• 11. Korkmaz HA, Arya VB, Barisik V, Atila D, Coskunol F, Alci S, Cekdemir YE, Torlak D, Özkan B. The Association between Vitamin D Deficiency and Hepatosteatosis in Children and Adolescents with Obesity. Horm Res Paediatr. 2024;97(4):326-333.
• 12. Yildiz I, Erol OB, Toprak S, Cantez MS, Omer B, Kilic A, Oguz F, Uysalol M, Yekeler E, Unuvar E. Role of vitamin D in children with hepatosteatosis. J Pediatr Gastroenterol Nutr. 2014 Jul;59(1):106-11.
• 13. Dursun F, Gerenli N, Dur SMS, Kirmizibekmez H. The relationship between vitamin D level and hepatosteatosis in obese children. North Clin Istanb. 2018 Aug 8;6(1):28-32.
• 14. Zúñiga S, Firrincieli D, Housset C, Chignard N. Vitamin D and the vitamin D receptor in liver pathophysiology. Clin Res Hepatol Gastroenterol 2011;35:295–302.
• 15. Basarir G, Ozcabi B, Aksu Sayman O, Ozturkmen Akay H, Yildiz FM. Evaluation of clinical, endocrine and metabolic findings in obese children with and without hepatosteatosis. J Pediatr Endocrinol Metab. 2021;34(9):1081-1087.
• 16. Aslan A, Erdemli S, Günaydın GD, Aslan M, Yazar RÖ, Kabaalioğlu A, Ağırbaşlı MA. Cardiometabolic risk factors in Turkish children with hepatosteatosis. Turk J Pediatr. 2019;61(5):714-722.
• 17. Lu CW, Lin MS, Lin YS, Chang IJ, Tsai MH, Wei KL, Chen MY. Aminotransferase Ratio Is a Useful Index for Hepatosteatosis in Children and Adolescents: A Cross-Sectional Observational Study. Gastroenterol Nurs. 2019;42(6):486- 495.
• 18. Agirbasli M, Cakir S, Ozme S, Ciliv G. Metabolic syndrome in Turkish children and adolescents. Metabolism 2006; 55: 1002-1006.